Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C173364
http://purl.obolibrary.org/obo/NCIT_C173364
|
|---|---|
| Preferred Name | Androgen Receptor Degrader CC-94676 |
| Definitions |
An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, AR degrader CC-94676 causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC).
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable androgen receptor (AR) degrader, with potential antineoplastic activity. Upon administration, AR degrader CC-94676 causes degradation of AR, prevents AR-mediated signaling and inhibits the proliferation of AR-overexpressing tumor cells. AR plays a key role in tumor cell proliferation in castration-resistant prostate cancer (CRPC). |
|---|---|
| prefLabel | Androgen Receptor Degrader CC-94676
|
| label | Androgen Receptor Degrader CC-94676
|
| NCI_META_CUI | CL1407191
|
| PDQ_Closed_Trial_Search_ID | 801809
|
| code | C173364
|
| Has_Target | |
| prefixIRI | NCIT:C173364
|
| in_subset |
See more
See less
|
| Display_Name | Androgen Receptor Degrader CC-94676
|
| Preferred_Name | Androgen Receptor Degrader CC-94676
|
| FDA_UNII_Code | VA228VR2DI
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Androgen Receptor Degrader CC-94676
|
| NCI_Drug_Dictionary_ID | 801809
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 801809
|
| Semantic_Type | Pharmacologic Substance
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |